Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life
About this episode
Moran Amit MD PhD discusses the potential of intralesional PD 1 blockade to reduce the risk of progression to oral cancer compared to surgery while preserving quality of life.
Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life An interview with: Moran Amit MD PhD, Head and Neck Surgeon, Assistant Professor, University of Texas MD Anderson Cancer Center, Houston, Texas USA. SAN DIEGO, USA—The risk that oral pre-cancerous lesions will progress to cancer may effectively be reduced by using intralesional injections of a checkpoint inhibitor, sparing the need for multiple surgical resections and the loss of oral function such surgery can bring. This hope was held out at the AACR 2026 Annual Meeting in San Diego by Moran Amit MD PhD, who is a head and neck surgeon and assistant professor, at the University of Texas MD Anderson Cancer Center in Houston, Texas. After reporting his new data to the conference he talked with our reporter, Peter Goodwin: IN: [GOODWIN] “I am at the American Association …. OUT: ……..the Audio Journal of Oncology, I’m Peter Goodwin 10:13 secs AACR 2006 ABSTRACT: CT188 Title: Intralesional PD1 blockade for Oral Cancer Prevention: First in Class Phase1 Trial Authors: Moran Amit, Robert Saddawi-Konefka, Shorook Naara, Fred Netto, Fred Netto, Chen F Fushun, Yen…
More episodes of Audio Journal of Oncology Podcast
- Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
- Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
- Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy
- Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors
- Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings
- Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.